Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Formulations for treating bladder cancer

a technology of liposomal and therapeutic drugs, applied in the direction of pharmaceutical delivery mechanism, drug composition, organic active ingredients, etc., can solve the problems of unpharmacologically acceptable dmso required to keep in solution an effective dose of bladder cancer treatment, drug administration obstacle,

Inactive Publication Date: 2021-09-02
TESORX PHARMA LLC
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this approach to administering drugs presents an obstacle to using drugs such as paclitaxel (Taxol®) to treat bladder cancer (Hadaschik et al., “Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer”BJUI.
While paclitaxel can be dissolved in dimethyl sulfoxide (DMSO), the amount of DMSO required to keep in solution an effective dose for bladder cancer treatment is not pharmaceutically acceptable.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Formulations for treating bladder cancer
  • Formulations for treating bladder cancer
  • Formulations for treating bladder cancer

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0051]

TABLE 1IngredientsQtyPaclitaxel (mw = 853.9 Da)  24 mgDMPG (mw = 688.9 Da; Tc = 23° C.)25.2 mgDMPC (mw = 677.9 Da; Tc = 24° C.)77.5 mgMannitol 100 mg

example 2

[0052]

TABLE 2IngredientsQtyPaclitaxel (mw = 853.9 Da)25.2 mgDMPG (mw = 688.9 Da; Tc = 23° C.)33.8 mgDMPC (mw = 677.9 Da; Tc = 24° C.)84.4 mgCholesterol (mw = 386.65 Da)20.1 mgMannitol  27 mg

example 3

[0053]

TABLE 3IngredientsQtyPaclitaxel27.4 mgDMPG12.2 mgDMPC90.4 mgMannitol  50 mg

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
pHaaaaaaaaaa
particle sizesaaaaaaaaaa
Login to View More

Abstract

Compositions and methods for making and using proliposomal and liposomal formulations of chemotherapeutic agents are disclosed. The proliposomal and liposomal formulations of chemotherapeutics, as well as medicaments and dosage forms that include such formulations, can be used with treatment regimens for bladder cancer and urothelial cancer. Hence, the formulations, medicaments, and dosage forms of the invention are suitable to treat bladder cancers by intravesical administration and to treat urothelial cancers. The formulations according to the invention include (a) a taxane (e.g., paclitaxel, docetaxel) or cisplatin, (b) a first phospholipid, dipalmitoyl phosphatidylcholine (DMPC), and (c) a second phospholipid, dimyrsityl phosphatidyl glycerol sodium (DMPG). The proliposomal formulations form liposomes upon contact with an aqueous vehicle.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a divisional application of U.S. application Ser. No. 16 / 066,836, filed Jun. 28, 2018; which is a 371 of PCT International Application No. PCT / US2017 / 012720, filed Jan. 9, 2017; which claims priority to U.S. Applications Nos. 62 / 275,941 and 62 / 275,936, both filed on Jan. 7, 2016, and 62 / 421,137, filed on Nov. 11, 2016, all of which are incorporated herein by reference.FIELD OF THE INVENTION[0002]The inventions described herein relate to proliposomal and liposomal formulations of therapeutic drugs, and their use in the treatment of bladder cancer.BACKGROUND[0003]The administration of chemotherapeutic drugs for the treatment of bladder cancer generally involves intravesicular administration of the drugs directly into the bladder, using a urinary catheter. However, this approach to administering drugs presents an obstacle to using drugs such as paclitaxel (Taxol®) to treat bladder cancer (Hadaschik et al., “Paclitaxel and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K9/127A61K31/337A61K9/00A61K9/19A61K33/243A61P35/00A61K47/24
CPCA61K9/1277A61K31/337A61K9/0034A61K47/24A61K9/127A61K33/243A61P35/00A61K9/19A61K47/28A61K2300/00
Inventor BETAGERI, GURU V.VENKATESAN, NATARAJANOEFELEIN, MICHAEL G.THIRUCOTE, RAMACHANDRANSWARNAKAR, NITIN KUMARHONG, TERESA
Owner TESORX PHARMA LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com